External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Neuroscience Autoimmune Encephalitis

Autoimmune Encephalitis

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Apr 23 / Roche
Moving upstream: The role of interleukin-6 in MOGAD and autoimmune encephalitis
This Industry Therapeutic Update (ITU) explores unmet needs, diagnosis and the evolving therapeutic landscape across a spectrum of autoantibody-driven autoimmune disorders, with a focus on myelin oligodendrocyte glycoprotein antibody disease (MOGAD) and autoimmune encephalitis (AE). Additionally, the session discusses perspectives on the diseases' pathophysiology including the potential role of interleukin-6 (IL-6) signalling.
Neuroscience Inflammatory Disease Autoimmune Encephalitis Myelin oligodendrocyte glycoprotein antibody disease AAN-2024

Sign up or login to unlock the full suite of MEDICALLY features
Apr 23 / Roche
Moving upstream: The role of interleukin-6 in MOGAD and autoimmune encephalitis
This Industry Therapeutic Update (ITU) explores unmet needs, diagnosis and the evolving therapeutic landscape across a spectrum of autoantibody-driven autoimmune disorders, with a focus on myelin oligodendrocyte glycoprotein antibody disease (MOGAD) and autoimmune encephalitis (AE). Additionally, the session discusses perspectives on the diseases' pathophysiology including the potential role of interleukin-6 (IL-6) signalling.
Neuroscience Inflammatory Disease Autoimmune Encephalitis Myelin oligodendrocyte glycoprotein antibody disease AAN-2024

Sign up or login to unlock the full suite of MEDICALLY features
Nov 30 / Roche and Genentech
CIELO: A Randomised, Double-Blind, Placebo-controlled, Phase 3 Basket Study of Satralizumab in Patients with NMDAR- or LGI1-antibody Encephalitis
CIELO is the first study to assess satralizumab in patients with AIE. CIELO will provide efficacy, safety, pharmacokinetics, and pharmacodynamics data for satralizumab in patients with NMDAR and LGI1 AIE.
Neuroscience Autoimmune Encephalitis ENCEPHALITIS-2022

Sign up or login to unlock the full suite of MEDICALLY features
Oct 23 / Roche and Genentech
CIELO: A Randomized, Double-Blind, Placebo-controlled, Phase 3 Study of Satralizumab in Patients with NMDAR or LGI1 Autoimmune Encephalitis
CIELO is the first study to assess satralizumab in patients with AIE. CIELO will provide efficacy, safety, pharmacokinetics, and pharmacodynamics data for satralizumab in patients with NMDAR and LGI1 AIE.
Neuroscience Autoimmune Encephalitis ANA-2022
Upcoming Congresses
Access to Roche and Genentech's medical information
View related congresses

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.